BioSpace News Archive

NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that Stephen Chen, NKGen Biotech’s Chief Technical Officer, will present at the Virtual Solebury Trout Fall Private Company Showcase.

BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first cross-over patient in the ongoing Phase III Pivotal CardiAMP® Cell Therapy in Heart Failure Trial for the treatment of ischemic heart failure.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment in INNATE tumor-specific expansion cohorts for both JTX-8064 monotherapy and combination therapy of JTX-8064 with its internal PD-1 inhibitor, pimivalimab.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient has been dosed in the Phase 1/2 study in Canada with three other patients enrolled and scheduled to begin dosing.

ViaCyte, Inc. announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021 , at 10:15 a.m. PT in Carlsbad, CA.

iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens (“iSpecimen” or the “Company”), today announced it is expanding its human biospecimen supplier network to offer increasingly comprehensive selections of whole blood, plasma and other biofluids to help accelerate the development of liquid biopsies.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial markets.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ/TSX: MDNA), a clinical stage immuno-oncology company, today announced the presentation of new preclinical data from its MDNA11 program in a virtual poster session at the AACR-NCI-EORTC Virtual International Conference On Molecular Targets and Cancer Therapeutics.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management.